ES2200851T3 - Variantes de peptido del marcador tumoral muc1 y su utilizacion. - Google Patents
Variantes de peptido del marcador tumoral muc1 y su utilizacion.Info
- Publication number
- ES2200851T3 ES2200851T3 ES00916753T ES00916753T ES2200851T3 ES 2200851 T3 ES2200851 T3 ES 2200851T3 ES 00916753 T ES00916753 T ES 00916753T ES 00916753 T ES00916753 T ES 00916753T ES 2200851 T3 ES2200851 T3 ES 2200851T3
- Authority
- ES
- Spain
- Prior art keywords
- peptide
- pap20
- seq
- muc1
- vntr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 38
- 102100034256 Mucin-1 Human genes 0.000 title claims abstract description 23
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 title claims abstract description 22
- 239000000439 tumor marker Substances 0.000 title description 3
- 150000001413 amino acids Chemical class 0.000 claims abstract description 10
- 101100084013 Arabidopsis thaliana PAP20 gene Proteins 0.000 claims abstract 2
- 101100098812 Mus musculus Tasor2 gene Proteins 0.000 claims abstract 2
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 10
- 239000000427 antigen Substances 0.000 claims description 5
- 102000036639 antigens Human genes 0.000 claims description 5
- 108091007433 antigens Proteins 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 229960005486 vaccine Drugs 0.000 claims description 5
- 230000009946 DNA mutation Effects 0.000 claims description 3
- 230000002163 immunogen Effects 0.000 claims description 3
- 238000012360 testing method Methods 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 8
- 229940024606 amino acid Drugs 0.000 description 7
- 201000009030 Carcinoma Diseases 0.000 description 4
- 108010063954 Mucins Proteins 0.000 description 3
- 102000015728 Mucins Human genes 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 229960002429 proline Drugs 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 108010008707 Mucin-1 Proteins 0.000 description 1
- 101710155891 Mucin-like protein Proteins 0.000 description 1
- 102100034937 Poly(A) RNA polymerase, mitochondrial Human genes 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 230000002032 cellular defenses Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 108090001092 clostripain Proteins 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000022811 deglycosylation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 102000057860 human MUC1 Human genes 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 235000021190 leftovers Nutrition 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 229940051875 mucins Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19906615 | 1999-02-17 | ||
| DE19906615A DE19906615A1 (de) | 1999-02-17 | 1999-02-17 | Peptid-Varianten des Tumormarkers MUC1 und ihre Verwendung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2200851T3 true ES2200851T3 (es) | 2004-03-16 |
Family
ID=7897778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES00916753T Expired - Lifetime ES2200851T3 (es) | 1999-02-17 | 2000-02-17 | Variantes de peptido del marcador tumoral muc1 y su utilizacion. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20090054622A1 (enExample) |
| EP (1) | EP1151005B1 (enExample) |
| JP (1) | JP2002541067A (enExample) |
| AT (1) | ATE243222T1 (enExample) |
| AU (1) | AU772709B2 (enExample) |
| CA (1) | CA2368309A1 (enExample) |
| DE (2) | DE19906615A1 (enExample) |
| DK (1) | DK1151005T3 (enExample) |
| ES (1) | ES2200851T3 (enExample) |
| WO (1) | WO2000049045A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1529060E (pt) * | 2002-07-22 | 2014-11-28 | Glycotope Gmbh | Processo para a produção de uma mucina imuno-estimuladora (muc1) |
| JP5978204B2 (ja) | 2010-04-19 | 2016-08-24 | 住友ベークライト株式会社 | 癌関連糖ペプチドエピトープ、抗体および使用方法 |
| CA2844500C (en) | 2011-08-17 | 2022-05-10 | Globeimmune, Inc. | Yeast-muc1 immunotherapeutic compositions and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3023469B2 (ja) * | 1992-02-21 | 2000-03-21 | 株式会社日本抗体研究所 | 糖タンパク質３９遺伝子 |
| US6120765A (en) * | 1993-04-02 | 2000-09-19 | Shiseido Co. Ltd. | Urokinase plasminogen activator fragments |
| US5744144A (en) * | 1993-07-30 | 1998-04-28 | University Of Pittsburgh University Patent Committee Policy And Procedures | Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof |
| WO1998037095A2 (en) * | 1997-02-24 | 1998-08-27 | Therion Biologics Corporation | Recombinant pox virus for immunization against muc1 tumor-associated antigen |
-
1999
- 1999-02-17 DE DE19906615A patent/DE19906615A1/de not_active Withdrawn
-
2000
- 2000-02-17 DE DE50002584T patent/DE50002584D1/de not_active Expired - Fee Related
- 2000-02-17 AT AT00916753T patent/ATE243222T1/de not_active IP Right Cessation
- 2000-02-17 JP JP2000599782A patent/JP2002541067A/ja active Pending
- 2000-02-17 EP EP00916753A patent/EP1151005B1/de not_active Expired - Lifetime
- 2000-02-17 DK DK00916753T patent/DK1151005T3/da active
- 2000-02-17 ES ES00916753T patent/ES2200851T3/es not_active Expired - Lifetime
- 2000-02-17 AU AU38013/00A patent/AU772709B2/en not_active Ceased
- 2000-02-17 CA CA002368309A patent/CA2368309A1/en not_active Abandoned
- 2000-02-17 WO PCT/DE2000/000440 patent/WO2000049045A1/de not_active Ceased
-
2001
- 2001-08-16 US US09/931,638 patent/US20090054622A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DE50002584D1 (de) | 2003-07-24 |
| WO2000049045A1 (de) | 2000-08-24 |
| AU772709B2 (en) | 2004-05-06 |
| ATE243222T1 (de) | 2003-07-15 |
| CA2368309A1 (en) | 2000-08-24 |
| JP2002541067A (ja) | 2002-12-03 |
| EP1151005A1 (de) | 2001-11-07 |
| US20090054622A1 (en) | 2009-02-26 |
| EP1151005B1 (de) | 2003-06-18 |
| DK1151005T3 (da) | 2003-10-13 |
| DE19906615A1 (de) | 2000-09-28 |
| AU3801300A (en) | 2000-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20230007287A (ko) | 사스-코로나바이러스-2 감염증 예방 또는 치료용 백신 조성물 | |
| ES2311027T3 (es) | Composiciones y metodos para la inmunoterapia especifica de wt1. | |
| ES2245783T3 (es) | Dominio intracelular de la proteina her-2/neu para la prevencion o el tratamiento de neoplasias malignas. | |
| McDonald et al. | Synthesis and immunological evaluation of self-adjuvanting MUC1-macrophage activating lipopeptide 2 conjugate vaccine candidates | |
| US8916514B2 (en) | CASB7439 constructs | |
| ES2398492T3 (es) | Proteínas de fusión que comprenden los antígenos de rechazo tumoral NY-ESO-1 y LAGE-1 | |
| KR20230084478A (ko) | 면역원성 코로나 바이러스 융합 단백질 및 관련 방법 | |
| ES2200851T3 (es) | Variantes de peptido del marcador tumoral muc1 y su utilizacion. | |
| JP2021522239A (ja) | 熱ショックタンパク質結合ペプチド組成物およびその使用方法 | |
| Li et al. | Design of a MUC1-based tricomponent vaccine adjuvanted with FSL-1 for cancer immunotherapy | |
| EP4238983A1 (en) | Vaccine composition for prevention or treatment of sars-coronavirus-2 infection | |
| NO20005081L (no) | Et polypeptid som omfatter aminosyren fra et N-terminalt kolinbindende protein A trunkat, vaksine avledet derav og anvendelser derav | |
| US10647749B2 (en) | Glycosylated YGHJ polypeptides from enterotoxigenic Escherichia coli (ETEC) | |
| JP2007525403A (ja) | ワクチン組成物および方法 | |
| ES2273670T3 (es) | Usos de polinucleotidos y polipeptidos casb618. | |
| JP2008536803A (ja) | 精子タンパク質に対する新規卵受容体 | |
| US11564983B1 (en) | Efficient expression system of SARS-CoV-2 receptor binding domain (RBD), methods for purification and use thereof | |
| JP4284490B2 (ja) | ｅｒｂＢ−２関連ペプチド | |
| US5272256A (en) | Nuclear autoantigen | |
| WO2009152986A1 (en) | Muc16 fragments with antigenic activity and pharmaceutical compositions thereof | |
| CN117957017A (zh) | 包含重组重叠肽和天然蛋白质的疫苗制剂 | |
| KR20230075625A (ko) | 스트렙토코커스 수이스의 면역원성 재조합 단백질 및 이를 포함하는 면역원성 조성물 | |
| ES2441880A1 (es) | Composición basada en polipéptidos para el tratamiento de miasis | |
| KR20220039078A (ko) | 사스-코로나바이러스-2의 변형된 스파이크 단백질을 포함하는 사스-코로나바이러스-2 감염증 예방 또는 치료용 백신 조성물 | |
| JP2022542120A (ja) | 抗原性ポリペプチドおよびその使用方法 |